Why Vaccinate Healthy 2- to 17-Year-Olds Against Influenza?
On February 2023, the French National Authority for Health (HAS) recommended extending flu shots to children aged 2-17 years without comorbidities.
The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research
In the last three years, extensive research has demonstrated the safety and efficacy of COVID-19 vaccines. These vaccines have played a critical role in reducing mortality and hospitalization rates.
Variant-adapted COVID-19 booster vaccines
Current vaccines should be tailored to combat future SARS-CoV-2 variants.
WHO/Europe, EC and ECDC urge eligible groups to get vaccinated or boosted to save lives this autumn and winter
Last year’s autumn and winter seasons were unpredictable. Last winter, the cumulative impacts of influenza, COVID-19, and respiratory syncytial virus or RSV hit the very young and the very old the hardest.
|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
Vaccine Monitoring Platform research agenda
The Vaccine Monitoring Platform (VMP) is a collaboration between EMA and ECDC for the timely generation of independent real-world evidence (RWE) on the safety and effectiveness of vaccines in use in EU/EEA immunisation programs.
COVID-19 pandemic: a catalyst for accelerating global action on patient safety
The disruption of health systems during the pandemic led to an increase in clinical risks and patient harm due to the accentuation of safety gaps, interruption of essential health services, and failure to provide timely diagnosis and treatment.
The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions
RSV causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon.
|
ESWI Airborne: Burden of Disease
Burden of disease - A focus on acute respiratory viruses in older adults
Why should older adults be particularly careful of acute respiratory viruses? What are risk factors for adverse outcomes? Why is RSV typically under-diagnosed in adults compared with flu and what are some of the long-term impacts?
|
ESWI Airborne: Burden of Disease
Burden of disease - The economic and societal impact of acute respiratory viruses
The shocking numbers of babies and children who die, or who are in need of care, coupled with the rising number of undiagnosed older adults puts a significant burden from RSV on health systems.
Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers
Antibody levels and neutralizing activity progressively increased with each booster but subsequently waned over 3-6 months.
United in Protection: vaccination is a show of solidarity!
Ahead of European Immunisation Week (EIW), taking place from 23 to 29 April 2023, Isabel de la Mata -principal advisor for Health and Crisis Management at the European Commission- talks about the benefits of lifelong vaccination
